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A Ab bs st tr ra ac ct t
Myeloproliferative neoplasms (MPNs) are a group of closely related stem-cell-derived clonal
proliferative diseases. Most cases are sporadic but first-degree relatives of MPN patients have a
five- to seven-fold increased risk for developing an MPN. The tumors of most patients carry a
mutation in the Janus kinase 2 gene (JAK2V617F). Recently, three groups have described a strong
association of JAK2 germline polymorphisms with MPN in patients positive for JAK2V617F. The
somatic mutation occurs primarily on one particular germline JAK2 haplotype, which may
account for as much as 50% of the risk to first-degree relatives. This finding provides new
directions for unraveling the pathogenesis of MPN.
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C Ca an nc ce er r   g ge en ne e   i id de en nt ti if fi ic ca at ti io on n
Although many cancers show familial clustering,
identification of the predisposing germline genes is
challenging. Mutations in genes such as p53,  BRCA1,
CDKN2 and HNPCC causing high risk of tumors (often at an
early age) were discovered from studies of rare families with
striking tumor clusters [1]. However, these mutations
explain only a small fraction of cancer susceptibility in the
general population. More common cancers among older
individuals also show familial aggregation and are probably
the result of a combination of germline genes and
environmental or other factors. The attempt to identify
common susceptibility genes with smaller effects has been
facilitated by the ability to conduct large-scale genome-wide
association studies in cases and controls.
Somatic changes found in tumors may also be a result of
germline susceptibility genes in the same region. Three
recent articles in Nature Genetics [2-4] successfully
demonstrate the potential of this approach by identifying a
gene involved in susceptibility to developing chronic
myeloproliferative neoplasms (MPNs) that is likely to have
both germline and somatic effects. It is useful to review the
recent history around this discovery and determine the
lessons learned that could be applied to other cancers.
G Ge en ne et ti ic cs s   o of f   m my ye el lo op pr ro ol li if fe er ra at ti iv ve e   n ne eo op pl la as sm ms s
On the basis of the current World Health Organization
criteria, MPNs include polycythemia vera (PV), essential
thrombocythemia (ET) and primary myelofibrosis (MF) [5].
They are all stem-cell-derived clonal proliferative diseases
whose shared and diverse phenotypic characteristics can be
attributed to dysregulated signal transduction because of
acquired somatic mutations [6]. They are uncommon
tumors with yearly incident rates of 2.3 in 100,000 in theUnited States [7] and primarily affect older adults, with a
variable clinical presentation. For example, approximately
half of all MPN patients are reported to be asymptomatic at
diagnosis [5,8]. Among PV and ET patients, the major
symptoms are associated with hypertension or vascular
abnormalities, including an increased risk for thrombo-
embolismand hemorrhage [9,10]. Also, patients with PV and
ET have an excess risk of developing MF, or transformation
to myelodysplastic syndrome or leukemia [9,10]. Although
available information is limited, life expectancy of patients
with ET has been reported to be similar to that of the general
population; however, for PV patients, life expectancy has
been observed to be reduced compared with the general
population [11]. In contrast, primary MF patients have an
average survival of less than 5years [12]. Currently, the
underlying causes of MPNs are mostly unknown.
A mutation in the gene for Janus kinase 2 (JAK2V617F) is
present in erythropoietin-independent erythroid colonies in
PV and gives a proliferative advantage in these cells. The
mutation is present in 95% of PV patients and in
approximately 50% of ET and MF patients [6]. However,
given that case studies have shown that only a minority of
granulocytes affected by a chromosome 20q deletion also
harbored JAK2V617F,other primary pathogenetic factors have
been suggested. It has also been demonstrated that rare
somatic events, such as a chromosome 20q deletion or loss
of heterozygosity on 9p, have occurred more than once in
subclones from the same patients, suggesting that the
myeloproliferative disorder clone carries a predisposition to
acquiring such genetic alteration [13]. A role for genetic
factors in the etiology of MPNs has alsobeen suggested from
case reports and smaller case series showing evidence of
familial clustering of PV, ET, MF and chronic myeloid
leukemia (CML) [14,15]. One study of patients from 72
families with different MPNs found no evidence for the
JAK2V617F mutation in the germline of patients who carried
the mutation in their tumor cells, and the authors concluded
that the JAK2 gene was a later ‘hit’ in these families [16].
We recently published a study [17] using Swedish Registry
data, showing that the risk of MPN in nearly 25,000 first-
degree relatives of 11,000 cases was significantly higher
(five- to seven-fold elevated) than in first-degree relatives of
control individuals. The results are illustrated in Figure 1.
We also found an approximately two-fold relative risk
(borderline significant) for CML in relatives of MPN patients.
In fact, a series of case reports has described co-existence of
the  JAK2  mutation and the BCR-ABL translocation, a
chromosomal abnormality associated with CML [18]. This
suggests that there is a strong important hereditary compo-
nent to MPN above and beyond the rare ‘heavily loaded’
families. We found elevated risks for PV, ET and MF among
relatives of MPN patients, suggesting that there is common
genetic susceptibility among the subtypes. We emphasized
in that article [17] that the high recurrence risks in relatives
made the search for germline risk genes compelling.
We did not have to wait long for the identification of a
germline susceptibility gene. The results from the three recent
studies all converge on the conclusion that the JAK2 gene is a
susceptibility gene for MPNs both in the germline and
somatically [2-4]. These studies demonstrated that the
malignant clone containing the JAK2 mutation was strongly
associated with a particular haplotype defined by nearby
single nucleotide polymorphisms (SNPs) in patients that were
JAK2V617F-positive. The study by Jones et al. [2] demonstrated
that a single haplotype was present in clones that were
homozygous for JAK2V617F. The association was also found in
a larger population of patients. Interestingly, in one family
with a grandparent and grandchild both with PV, only one of
the cases had the at-risk haplotype. One of the associated
SNPs was also shown to be in cis with the JAK2V617F allele in
the study by Olcaydu et al. [4]. Another nearby SNP was
almost always found in cis with  JAK2V617F in the study by
Kilpivaara et al. [3] In all three studies, these SNPs showed
high relative risks when JAK2V617F-positive patients were
compared with controls. Kilpivaara et al. [3] also presented
association of genome-wide markers in cases and controls and
showed that the JAK2 SNP was highly significant even in the
context of a genome-wide search. The article by Jones et al.
[2] showed weak evidence that the risk haplotype was also
associated with JAK2V617F-negative patients.
F Fu ut tu ur re e   d di ir re ec ct ti io on ns s
The evidence is now in favor of the JAK2  locus being an
important germline and somatic hit in the pathology of
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F Fi ig gu ur re e   1 1
Risk for specific MPNs among first-degree relatives of MPN patients. The
bars show relative risk estimates for specific MPNs (given on the x-axis)
among first-degree relatives of patients affected with specific MPNs (see
key) compared with first-degree relatives of controls.
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Key:MPNs. The authors of the three studies [2-4] have specu-
lated possible mechanisms. One possibility is that the
associated SNPs are in linkage disequilibrium with an
unidentified functional variant. Other possibilities are that
the associated haplotype causes the JAK2 gene to be more
susceptible to mutation or allows increased survival of
JAK2V617F alleles.
But what about the high-risk families that have been
described? As mentioned above, Bellanné-Chantelot et al.
[16] did not find the JAK2V617F mutation in the germline in
MPN families and also did not see evidence for linkage to the
JAK2 region of chromosome 9. It is possible that the JAK2
region has a role in some families but that other rare loci
also exist. It is also likely that there are other common genes
that contribute to risk in the population. Jones et al. [2]
estimate that the JAK2-associated haplotype accounts for
50% of the risk in first-degree relatives on the basis of our
relative risk estimate of 5.7 in first-degree relatives of PV
patients [17]. Thus, there are likely to be additional common
and rare susceptibility genes. Nevertheless, these new
findings are a large step in the progress towards
understanding the pathogenesis of MPN.
A Ab bb br re ev vi ia at ti io on ns s
CML, chronic myeloid leukemia; ET, essential thrombo-
cythemia; MF, myelofibrosis; MPN, myeloproliferative
neoplasm; PV, polycythemia vera; SNP, single nucleotide
polymorphism.
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